All articles tagged with #dexcom
Originally Published 6 months ago — by Financial Times
US health secretary Robert Kennedy Jr. endorsed the use of health wearables, prompting a surge in shares of DexCom and other medical device makers, as he announced plans to promote wearable technology for health monitoring across the US within four years, highlighting the growing interest and investment in health tracking devices.
Originally Published 1 year ago — by TechCrunch
Oura, the smart ring maker, has secured a $75 million investment from glucose monitoring device firm Dexcom, raising its valuation to over $5 billion. This partnership will integrate Oura's rings with Dexcom's glucose monitoring technology, allowing users to track blood sugar levels and make informed health decisions. The first app integration is expected by mid-2025. Oura, which has sold 2.5 million rings, anticipates doubling its sales in 2024. This collaboration positions Oura and Dexcom against competitors like Apple, which is also exploring noninvasive glucose monitoring solutions.
Originally Published 1 year ago — by Quartzy
Oura smart rings will soon offer enhanced blood sugar monitoring capabilities through a partnership with Dexcom, the maker of the first over-the-counter continuous glucose monitor in the U.S. This collaboration aims to integrate Oura's health data with Dexcom's glucose insights, providing users with a comprehensive view of their health. The first app integration is expected by mid-2025, and Dexcom is investing $75 million in Oura's Series D funding. This partnership will allow users to make informed lifestyle choices based on their glucose levels and other health metrics.
Originally Published 1 year ago — by CNBC
Signos is a startup offering a subscription service that includes a small continuous glucose monitor (CGM) and an app that aims to help users lose weight by tracking their blood sugar. The CGM, which is not intended for diabetes management, sends data to the app to provide personalized insights into how the body responds to specific foods and daily habits like diet, exercise, stress, and sleep. While the platform offers valuable insights, it comes with a high price tag and may not be covered by insurance for non-diabetic users. Users should be mindful of their mental health and consult with a doctor before using the technology.
Originally Published 1 year ago — by USA TODAY
The FDA has approved the first over-the-counter continuous glucose monitor, the Stelo Glucose Biosensor System, designed for people 18 and older who don't use insulin and are treating diabetes with oral medications, as well as adults who want to track glucose levels. The wearable sensor pairs with a smartphone app to monitor, record, and analyze glucose values every 15 minutes, and can be used for up to 15 days before replacement. However, it is not designed to alert users about low blood sugar levels, and medical decisions should not be made based solely on its output without consulting healthcare providers. Dexcom plans to make the Stelo available this summer, with pricing expected to be competitive.
Originally Published 1 year ago — by 9to5Mac
The FDA has approved Dexcom's Stelo Glucose Biosensor System, an iPhone-enabled blood glucose monitor that does not require a prescription, aimed at non-insulin dependent diabetics and those at risk of developing diabetes. The device uses a wearable sensor and smartphone app to continuously measure and display glucose values, with measurements taken automatically every 15 minutes. It is intended for individuals 18 years and older who do not use insulin, providing greater health equity by moving care and wellness into the home setting. The device is set to go on sale in the US this summer, offering a step towards the long-term goal of non-invasive blood sugar measurement.
Originally Published 1 year ago — by Engadget
The FDA has approved Dexcom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor (CGM) for adults 18 and up who are not using insulin, providing a tool for managing diabetes with oral medications and for non-diabetics looking to control sugar intake. The device pairs with a smartphone app to display blood glucose measurements and trends every 15 minutes, and will be available this summer, offering a 15-day patch option for those without insurance coverage for CGM.
Originally Published 1 year ago — by STAT
The FDA has cleared Dexcom to sell the Stelo, a continuous glucose monitor, over-the-counter to adults without insulin dependence, with the product set to launch this summer. The device is designed for people with type 2 diabetes and those without diabetes who want to monitor their blood sugar levels. Paired with a smartphone app, it provides glucose measurements every 15 minutes. This move marks a significant expansion in access to continuous glucose monitoring technology, which has become a lucrative market for companies like Dexcom and Abbott.
Originally Published 1 year ago — by CNBC
Dexcom has received FDA clearance for its over-the-counter continuous glucose monitor, Stelo, designed for Type 2 diabetes patients who do not use insulin. This marks the first glucose biosensor not requiring a prescription, making it accessible to those without insurance coverage for CGMs. The device, to be available online this summer, offers real-time glucose tracking and lasts up to 15 days. Dexcom aims to provide a simpler experience tailored for Type 2 patients and plans to eventually secure insurance coverage for Stelo.
Originally Published 2 years ago — by Mass Device
The 2024 J.P. Morgan Healthcare Conference featured updates from industry leaders including Medtronic, Abbott, Shockwave Medical, Dexcom, and Johnson & Johnson MedTech. Medtronic focused on restoring earnings power and highlighted growth opportunities in cardiac ablation, diabetes, and structural heart, while also announcing the creation of the Medtronic AI Center of Excellence. Abbott touted the success of its FreeStyle Libre continuous glucose monitoring device and its plans for further growth, while Shockwave Medical emphasized product launches and global expansion efforts. Dexcom unveiled its new Stelo sensor designed for people with type 2 diabetes, and Johnson & Johnson MedTech highlighted its growth through M&A activities and recent developments in surgical robotics and pulsed field ablation.
Originally Published 2 years ago — by Investor's Business Daily
Nvidia and Arista Networks lead a list of five stocks near buy points, which also includes Datadog, Mastercard, and DexCom. Nvidia's stock has been performing well, with a potential new buy point if it clears the top of its range. Arista Networks has found support at its 21-day line and could offer an entry point if it moves higher. Datadog has a long cup-with-handle base and is about 6% shy of a buy zone. Mastercard and DexCom are showing strength in the payment processing sector, with Mastercard flirting with a flat-base buy point and DexCom updating its long-term financial guidance.
Originally Published 2 years ago — by CNBC
Abbott and Dexcom are the two most dominant players in the continuous glucose monitoring space, which has seen increased growth over the last decade. The technology is not only being marketed to diabetics but also to those who don't have diabetes for health and wellness purposes.